Generic drug
Tobramycin price, strengths & recalls
Generic of Tobrex
Pharmacies pay $5.48 for 5 mL of Tobramycin 3 mg/mL eye drops this week, and from $5.48 to $295.34 across its 3 priced strengths and forms. 42 manufacturers make it. It is in shortage (being discontinued). 6 recalls are ongoing. Its official label last changed on February 14, 2024.
Being discontinued6 open recallsGeneric- Fair cash price
- $16.80
- Strengths
- 3
- Makers
- 42
- Updated
- Nov 11
Tobramycin price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 3 mg/mL eye drops | $1.10 | $5.48 / 5 mL | ||
| 60 mg/mL inhalation solution | $1.05 | $295.34 / 280 mL | ||
| 75 mg/mL inhalation solution | Not priced this week | |||
| 40 mg/mL injection | $0.9279 | $46.40 / 50 mL | ||
Brand names of tobramycin
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Shortages
- Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01)Discontinuation of the manufacture of the drug
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 27 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Tobramycin
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use TOBRAMYCIN for injection safely and effectively. See full prescribing information for TOBRAMYCIN for injection.TOBRAMYCIN for Injection, for intravenous use Initial U.S. Approval: 1975
WARNING: NEPHROTOXICITY, OTOTOXICITY AND EMBRYO-FETAL TOXICITY
WARNING: NEPHROTOXICITY, OTOTOXICITY, NEURO MUSCULAR BLOCKADE AND FETAL HARM
See full prescribing information for complete boxed warning.
Nephrotoxicity
Tobramycin for Injection may cause acute kidney injury. Monitor renal function and serum tobramycin concentrations in all patients. Reduce the dose or discontinue the Tobramycin for Injection if renal impairment occurs. (5.1)
Ototoxicity
Tobramycin for Injection may cause irreversible auditory and vestibular toxicity. Monitor for symptoms of ototoxicity, and for renal function and serum tobramycin levels in all patients. Reduce the dose or discontinue the Tobramycin for Injection if impairment of renal function occurs. Discontinue Tobramycin for Injection if ototoxicity occurs. (5.2)
Neuromuscular Blockade
Aminoglycosides have been associated with neuromuscular blockade. During therapy with Tobramycin for Injection, monitor for adverse reactions associated with neuromuscular blockade, particularly in high-risk patients (5.5)
Embryo-Fetal Toxicity
Tobramycin for Injection and other aminoglycosides can cause fetal harm when administered to a pregnant woman. Apprise pregnant women of the potential hazard to the fetus. (5.3, 8.1)
Nephrotoxicity
Tobramycin for Injection can result in acute kidney injury, including acute renal failure. Risk factors that may contribute to nephrotoxicity include tobramycin accumulation (increasing serum trough levels), high peak concentrations (above 12 mcg/mL), total cumulative dose, advanced age, volume depletion and concurrent or sequential use of other nephrotoxic drugs. Avoid concurrent or sequential use of other potentially nephrotoxic drugs. Monitor serum tobramycin levels and renal function in all patients during drug treatment. Reduce the dose or discontinue the Tobramycin for Injection if renal impairment occurs
[see Warnings and Precautions
(5.1)].
Ototoxicity
Tobramycin for Injection can cause irreversible auditory and vestibular toxicity that may continue to develop after the drug has been discontinued. Risk factors include high serum concentrations, prolonged therapy, renal impairment, concurrent and sequential use of other nephrotoxic or ototoxic drugs (e.g. aminoglycosides), and extremes of age. Avoid concurrent or sequential use with other potentially ototoxic drugs. Monitor for signs and symptoms of auditory and vestibular toxicity. Reduce the dose or discontinue the Tobramycin for Injection if renal impairment occurs. Discontinue the Tobramycin for Injection if ototoxicity occurs.
[see Warnings and Precautions (5.2)].
Neuromuscular Blockade
Aminoglycosides have been associated with neuromuscular blockade. During therapy with Tobramycin for Injection, monitor for adverse reactions associated with neuromuscular blockade, particularly in high-risk patients, such as patients with underlying neuromuscular disorders (including myasthenia gravis) or in patients concomitantly receiving neuromuscular blocking agents
[see Warnings and Precautions (5.5)].
Embryo-Fetal Toxicity
Tobramycin and other aminoglycosides can cause fetal harm when administered to a pregnant woman. If Tobramycin for Injection is used during pregnancy or if the patient becomes pregnant while taking tobramycin, apprise the patient of the potential hazard to the fetus
[see Warnings and Precautions (5.3) and Use in Specific Populations (8.1)].
Recent major changes (as listed on the label)
Warnings and Precautions, Ototoxicity (5.2)
| 2/2023
|
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA050789 · Fresenius Kabi USA
- First approved
- July 13, 2004 (22 years ago)
- Latest approved change
- February 10, 2023
- Approved label
- PDF, Feb 13, 2023
- Generic makers
- 26 approved generic applications on the market
Tobramycin questions
How much does tobramycin cost without insurance?
Pharmacies pay about $5.48 for 5 mL of tobramycin 3 mg/mL eye drops ($1.10 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $16.80. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of tobramycin?
Tobramycin is sold as Tobrex. The generic has the same active ingredient and usually costs far less.
Is tobramycin in shortage?
Yes. 1 product is listed as in shortage or being discontinued (being discontinued). See which ones.
Has tobramycin been recalled?
27 recalls on record, 6 ongoing. Recalls name specific lots - check yours.
When did the tobramycin label last change?
The official label was last updated on February 14, 2024 (version 3). See what changed.
Talk about tobramycin
No comments yet. Questions, tips, what worked for you - start the conversation.